Share This Page
Drugs in ATC Class A10BK
✉ Email this page to a colleague
Drugs in ATC Class: A10BK - Sodium-glucose co-transporter 2 (SGLT2) inhibitors
SGLT2 Inhibitor Market and Patent Landscape: A10BK Analysis
Executive Summary
The market for Sodium-Glucose Co-transporter 2 (SGLT2) inhibitors, classified under ATC code A10BK, is characterized by significant innovation and a robust patent portfolio. This class of antidiabetic drugs has expanded beyond glycemic control to demonstrate cardiovascular and renal benefits, driving substantial revenue growth. Key patent filings focus on novel molecular entities, formulations, methods of use, and manufacturing processes. The competitive landscape is dominated by a few major pharmaceutical companies, with ongoing patent litigation and the emergence of biosimil/generic competition shaping future market dynamics.
What is the Therapeutic Area for ATC Class A10BK?
ATC Class A10BK encompasses drugs used for diabetes mellitus, specifically those that inhibit Sodium-Glucose Co-transporter 2 (SGLT2). SGLT2 is a protein primarily found in the kidneys responsible for reabsorbing glucose from the glomerular filtrate back into the bloodstream. By inhibiting SGLT2, these drugs reduce glucose reabsorption, leading to increased urinary glucose excretion and thereby lowering blood glucose levels. This mechanism of action is insulin-independent.
Which Drugs Belong to ATC Class A10BK?
The primary drugs within the A10BK classification include:
- Canagliflozin (marketed as Invokana, Invokamet)
- Dapagliflozin (marketed as Farxiga, Xigduo XR)
- Empagliflozin (marketed as Jardiance, Synjardy)
- Ertugliflozin (marketed as Steglatro, Segluromet)
- Sotagliflozin (marketed as Zynquista) - Note: Sotagliflozin also inhibits SGLT1, but its primary development and marketing indications align with the expanded benefits seen in A10BK drugs.
What are the Primary Indications for SGLT2 Inhibitors?
Initially approved for glycemic control in type 2 diabetes mellitus (T2DM), the indications for SGLT2 inhibitors have significantly expanded due to their demonstrated benefits in reducing cardiovascular and renal events.
Current primary indications include:
- Type 2 Diabetes Mellitus (T2DM): Improving glycemic control in adults, often as monotherapy or in combination with other antidiabetic agents.
- Cardiovascular Risk Reduction: Reducing the risk of major adverse cardiovascular events (MACE) in adults with T2DM and established cardiovascular disease (CVD).
- Heart Failure (HF): Reducing the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic chronic heart failure, with or without T2DM.
- Chronic Kidney Disease (CKD): Reducing the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death, and non-fatal myocardial infarction in adults with CKD, with or without T2DM.
What is the Market Size and Growth Trajectory for SGLT2 Inhibitors?
The global SGLT2 inhibitor market has experienced substantial growth, driven by expanded indications beyond diabetes, particularly for cardiovascular and renal protection.
- 2023 Estimated Market Size: The SGLT2 inhibitor market was estimated to be between $25 billion and $30 billion globally in 2023.
- Projected Growth: The market is forecast to continue its upward trajectory, with compound annual growth rates (CAGR) projected between 8% and 12% over the next five to seven years.
- Key Market Drivers:
- Increasing prevalence of T2DM worldwide.
- Growing awareness and clinical adoption of SGLT2 inhibitors for cardiovascular and renal benefits.
- Robust clinical trial data supporting these expanded indications.
- Product launches in emerging markets.
- Combination therapies offering enhanced patient management.
- Market Restraints:
- Patent expirations and the advent of generic competition for older SGLT2 inhibitors.
- Concerns regarding potential side effects, such as genitourinary infections and diabetic ketoacidosis (DKA), although incidence is generally low.
- Reimbursement challenges in certain healthcare systems.
What is the Patent Landscape for SGLT2 Inhibitors?
The patent landscape for SGLT2 inhibitors is complex and dynamic, characterized by a mix of composition of matter patents, formulation patents, method of use patents, and manufacturing process patents.
Key Patent Holders and Portfolio Strengths:
The major pharmaceutical companies with significant patent portfolios in the SGLT2 inhibitor space include:
- AstraZeneca: Holds key patents for dapagliflozin and its fixed-dose combinations.
- Janssen (Johnson & Johnson): Holds patents for canagliflozin and its fixed-dose combinations.
- Boehringer Ingelheim & Eli Lilly and Company: Share a strong patent portfolio for empagliflozin and its fixed-dose combinations.
- Merck & Co.: Holds patents for ertugliflozin.
- Lexicon Pharmaceuticals & Sanofi: Co-develop sotagliflozin, with associated patent protection.
Types of Patents and Their Significance:
| Patent Type | Description | Significance |
|---|---|---|
| Composition of Matter | Covers the novel chemical entity of the SGLT2 inhibitor molecule. | Provides the broadest protection, preventing others from making, using, or selling the compound itself. |
| Formulation | Protects specific drug delivery systems, dosage forms (e.g., tablets, extended-release), or excipient combinations. | Extends market exclusivity by protecting improved drug delivery or patient convenience. |
| Method of Use | Claims specific therapeutic uses of the SGLT2 inhibitor (e.g., treating T2DM, reducing cardiovascular risk). | Crucial for protecting expanded indications and can provide exclusivity even after composition of matter patents expire. |
| Manufacturing Process | Covers specific methods for synthesizing or purifying the SGLT2 inhibitor. | Protects efficient or novel manufacturing routes, potentially creating barriers to generic entry. |
| Polymorphs/Salts | Protects specific crystalline forms or salt forms of the active pharmaceutical ingredient (API). | Can extend exclusivity by protecting stable or bioavailable forms of the drug. |
Timeline of Key Patent Expirations:
The timing of patent expiries is critical for understanding the future competitive landscape and the potential for generic entry.
- Canagliflozin: Original composition of matter patents have largely expired or are nearing expiration in major markets (e.g., US: 2027; EU: 2025). However, method of use patents for cardiovascular and renal benefits extend exclusivity for specific indications.
- Dapagliflozin: Similar to canagliflozin, composition of matter patents are expiring. Method of use patents for heart failure and CKD provide extended protection. (e.g., US: 2029; EU: 2026).
- Empagliflozin: Composition of matter patents are also nearing expiration. Method of use patents for cardiovascular and renal outcomes are significant assets. (e.g., US: 2027; EU: 2025).
- Ertugliflozin: Being a more recent entrant, its patent protection extends further, with key patents expiring in the early to mid-2030s.
Patent Litigation:
The SGLT2 inhibitor space has seen and continues to experience significant patent litigation. This typically involves challenges to patent validity by generic manufacturers or disputes over patent infringement.
- Key Litigation Areas:
- Challenges to the validity of core composition of matter patents.
- Disputes over infringement of method of use patents, particularly concerning off-label promotion versus on-label use for expanded indications.
- Litigation concerning fixed-dose combination products.
- Impact of Litigation: Successful litigation by generic manufacturers can lead to earlier market entry for generic versions, significantly impacting the revenue streams of originator products. Conversely, successful defense of patents by originators extends market exclusivity.
What are the Emerging Trends and Future Outlook?
The SGLT2 inhibitor market is poised for continued evolution, driven by ongoing research, regulatory approvals, and market dynamics.
Key Emerging Trends:
- Combination Therapies: Development and approval of fixed-dose combination products with other antidiabetic agents (e.g., DPP-4 inhibitors, metformin) and, increasingly, with agents targeting different mechanisms for cardiovascular and renal protection.
- Expansion to New Indications: Research continues into potential benefits in other disease areas, such as non-alcoholic steatohepatitis (NASH), certain types of cancer, and other renal disorders.
- Biosimilar/Generic Competition: As primary patents expire, the market will increasingly face competition from biosimilar (for biologic drugs, not directly applicable here) or generic versions. The first wave of generic SGLT2 inhibitors is expected in key markets starting in the mid-2020s.
- Development of Next-Generation Inhibitors: Research is ongoing for SGLT2 inhibitors with improved efficacy, safety profiles, or novel pharmacokinetic properties.
- Focus on Real-World Evidence: Increasing emphasis on real-world data to confirm and expand upon the benefits observed in clinical trials, particularly for cardiovascular and renal outcomes.
- Global Market Penetration: Efforts to increase access and prescription of SGLT2 inhibitors in emerging markets, where the burden of diabetes and cardiovascular disease is growing rapidly.
Future Market Dynamics:
- Increased Generic Penetration: Post-patent expiry, generic versions will drive down prices and increase accessibility, potentially expanding the overall market volume.
- Shifting Market Share: Originator products with strong patent protection for their expanded indications (cardiovascular, renal) will likely maintain significant market share longer.
- Innovation in Combinations: Further innovation in dual and triple therapy combinations targeting multiple pathways will be critical for differentiating products.
- Impact of Health Economics: Cost-effectiveness analyses will play a larger role in formulary decisions and prescribing patterns, particularly as generic competition emerges.
Key Takeaways
- The SGLT2 inhibitor market (A10BK) is a high-growth sector driven by expanded therapeutic indications beyond glycemic control to include cardiovascular and renal protection.
- Major pharmaceutical companies hold extensive patent portfolios, with current protection focusing on composition of matter, formulations, and, critically, methods of use for advanced indications.
- Key patent expiries for the first-generation SGLT2 inhibitors are occurring in the mid-to-late 2020s, paving the way for generic competition.
- Method of use patents for cardiovascular and renal benefits offer extended market exclusivity for originator products.
- The market is characterized by active patent litigation, which significantly influences the timing and nature of generic entry.
- Future market dynamics will be shaped by generic competition, continued innovation in combination therapies, and the pursuit of new therapeutic indications.
Frequently Asked Questions
-
When are the primary composition of matter patents for empagliflozin expected to expire in the United States and the European Union? The primary composition of matter patents for empagliflozin are expected to expire in the United States around 2027 and in the European Union around 2025. However, method of use patents for specific indications may extend market exclusivity for certain applications.
-
Beyond type 2 diabetes, what are the most significant approved therapeutic areas for SGLT2 inhibitors that drive their market value? The most significant approved therapeutic areas driving market value beyond type 2 diabetes are the reduction of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and the treatment of symptomatic chronic heart failure. Additionally, their role in slowing the progression of chronic kidney disease is a major market driver.
-
What types of patent challenges are most common in the SGLT2 inhibitor space as key patents approach expiration? Common patent challenges include validity challenges to core composition of matter patents and disputes over infringement of method of use patents, particularly concerning the scope of claims related to cardiovascular and renal outcomes. Generic manufacturers often seek to invalidate these patents or argue non-infringement.
-
How does the emergence of fixed-dose combination products impact the patent strategy for SGLT2 inhibitors? Fixed-dose combination products can create new patentable subject matter, extending market exclusivity beyond the expiry of individual component patents. Companies file patents for novel combinations of SGLT2 inhibitors with other antidiabetic agents or cardiovascular/renal protective drugs, as well as for specific dosage forms and manufacturing processes for these combinations.
-
What is the expected impact of generic SGLT2 inhibitors on pricing and market volume in the near term? The introduction of generic SGLT2 inhibitors is expected to lead to a significant decrease in drug prices, similar to trends seen with other drug classes upon generic entry. This price reduction, combined with increased accessibility, is anticipated to drive an expansion in overall market volume, even as originator revenues may decline due to competition.
Citations
[1] World Health Organization Collaborating Centre for Drug Statistics Methodology. (n.d.). ATC/DDD Index. Retrieved from https://www.whocc.no/atc_ddd_index/ [2] Pharmaceutical market research reports and company financial disclosures (various sources, including IQVIA, Evaluate Pharma, and company annual reports). Data reflects estimates and projections available as of early 2024. Specific figures are aggregated and represent common industry consensus. [3] U.S. Food and Drug Administration (FDA) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (n.d.). Retrieved from https://www.fda.gov/drugs/information-drug-products/orange-book-approved-drug-products-therapeutic-equivalence-evaluations [4] European Medicines Agency (EMA) website. (n.d.). Retrieved from https://www.ema.europa.eu/ [5] United States Patent and Trademark Office (USPTO) database. (n.d.). Retrieved from https://www.uspto.gov/patents [6] European Patent Office (EPO) database (Espacenet). (n.d.). Retrieved from https://worldwide.espacenet.com/
More… ↓
